The present invention relates to a method of preparation of discrete particles of nanocrystalline solid dispersion, wherein said discrete particle comprises crystals of said active ingredient(s) in the matrix of the said crystallization inducer(s) and/or coexisting with crystals of crystallization inducer(s), optionally along with pharmaceutically acceptable excipient(s). An active ingredient and crystallization inducer is dissolved in a solvent or solvent mixture and then dried to obtain discrete particles of 0.5 to 20 micron size. Each particle consists of crystals of active ingredient in the range of 10-1000 nm dispersed in the matrix of crystallization inducer.

A fortified salt mixture includes sodium chloride salt grains and a multi-supplement food-additive admixed with the sodium chloride salt grains. The multi-supplement food additive includes particles, and each particle includes a core having a first supplement and a binder, a coating on the core, and a second supplement in the core and/or in the coating. A method for fortifying salt ncludes combining a first supplement, a second supplement, a binder and a coating to yield a multi-supplement food-additive; and admixing the multi-supplement food-additive with sodium chloride salt grains.

A fortified salt mixture includes sodium chloride salt grains and a multi-supplement food-additive admixed with the sodium chloride salt grains. The multi-supplement food additive includes particles, and each particle includes a core having a first supplement and a binder, a coating on the core, and a second supplement in the core and/or in the coating. A method for fortifying salt ncludes combining a first supplement, a second supplement, a binder and a coating to yield a multi-supplement food-additive; and admixing the multi-supplement food-additive with sodium chloride salt grains.

A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10.sup.−4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.

A composition essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein; wherein the ClpB protein is in an amount of at least 0.7% (w/w) in weight relative to the total weight of the composition; and the ratio of the total number of Hafnia alvei Colony Forming Units to the total Hafnia alvei cell number ranges from 10.sup.−4 to 0.8. Also, oral dosage forms, namely gastro-resistant capsules including the composition of essentially made of a Hafnia alvei probiotic strain expressing the ClpB protein.

A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

The present invention provides stable amorphous calcium carbonate (ACC) compositions, and food articles comprising said compositions.

A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential, and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.